For rehabilitation clinics · Physical and occupational therapy

A home walking program your therapists can see

evergait™ Go is a prescription device for adults with uneven walking after stroke. Your clinic fits it and runs the first sessions. The patient continues at home, and every walk comes back to the therapist.

It brings the principle behind split-belt treadmill training to everyday walking, without the treadmill, and it is designed to fit inside a standard therapy visit.

✓Prescription only
✓FDA: Class II, 510(k)-exempt device type¹
✓No capital equipment, no dedicated room

Illustration: a physical therapist supervising a stroke survivor walking with evergait™ Go in a clinic — Illustration

How it fits your clinic

The clinic prescribes, fits and supervises. The patient keeps walking between visits, and the therapist sees each session.

Step 1
Prescribe
A neurologist, physiatrist or therapist prescribes evergait™ Go for an adult with uneven walking after a stroke or another neurological condition.
Step 2
Fit in a standard visit
The clinic fits the device over the patient's own shoe on the unaffected side, pairs the two motion sensors and sets the walking plan in the app.
Step 3
Supervised sessions
The first walks happen in the clinic. Each session is up to 30 minutes of walking with rest breaks.
Step 4
Continue at home
When the therapist decides the patient is ready, sessions continue at home on flat indoor surfaces, with a caregiver present for the first home sessions.
Step 5
Review and adjust
The sensors record steps and walking pattern. The app sends each session to the clinic so the therapist can review progress and adjust the plan.

What your clinic gets

No capital equipment. The device is worn over the patient's own shoe. No treadmill and no dedicated room.
Practice between visits. Patients keep walking at home on the plan the therapist set.
Visibility. Session time, step count and sessions completed come back to the clinic. The clinician dashboard that receives them is in development.
A studied protocol. The published studies used 12 sessions of 30 minutes, three a week for four weeks.

App design concept: the motion sensor screen, showing left and right sensors connected and today's plan from the therapist — Planned app design. Screens may change before release.

Which patients

Intended for adults with uneven walking after a stroke or another neurological condition, typically six months or more after the stroke, who can walk on their own for at least 10 minutes with rest breaks. The prescribing clinician decides whether it is right for each patient.

What the published studies found

The technology now known as evergait™ Go has been clinically evaluated: five peer-reviewed studies under previous names and implementations, including the Gait Enhancing Mobile Shoe (GEMS) and the iStride™ Device, in the clinic and at home.

Study	Setting and participants	Reported results
Kim et al., 2019 J NeuroEng Rehabil	Clinic. 6 people more than a year after stroke. 12 sessions over 4 weeks, 30 minutes of walking each.	All six improved step length symmetry and all three functional measures (gait velocity, Timed Up and Go, 6-Minute Walk Test).
Huizenga et al., 2020 Top Stroke Rehabil	Home. 21 people more than a year after stroke. 12 sessions of 30 minutes.	Statistically significant improvement on all five outcome measures one week after treatment. 15 of 21 (71%) improved gait speed beyond the minimal clinically important difference.
Darcy et al., 2023 JMIR Form Res	Home, by telehealth with a care partner. 5 people. 3 months.	No serious adverse events. 95% of treatment sessions completed. Average improvement on each functional outcome exceeded the minimal clinically important difference or minimal detectable change.
Darcy et al., 2024 Front Neurol	Home. 18 people at least a year after stroke. 12 sessions of 30 minutes, followed for 12 months.	Average gait speed gain of more than 0.21 m/s at every follow-up through 12 months. 17 of 18 (94%) improved gait speed beyond the minimal clinically important difference at one or more follow-ups.
Darcy et al., 2025 JMIR Form Res	Home. 18 people with chronic stroke. 12 sessions of 30 minutes, followed for 12 months.	Improvements on the Berg Balance Scale, Timed Up and Go and Functional Gait Assessment remained statistically significant at every follow-up through 12 months.

All five were single-group studies without a control group. They evaluated the technology now known as evergait™ Go under previous names and implementations, including the Gait Enhancing Mobile Shoe (GEMS) developed at USF and the iStride™ Device made by Moterum Technologies under a prior USF license, and most authors of the 2020 to 2025 papers were with Moterum. These are published research findings, not FDA-reviewed claims about safety or effectiveness. A controlled clinical trial of evergait™ Go, delivered in the clinic and then at home, is planned. Full research and publications →

Reimbursement: what we know so far

Medicare pays for remote therapeutic monitoring (RTM): device set-up and patient education, the device supply, and the treatment management time a therapist spends reviewing data and working with the patient. Physical and occupational therapists can bill RTM under a plan of care.²

Whether evergait™ Go qualifies for RTM, and under which codes, has not yet been confirmed. Medicare's proposed rule for 2027 would also change RTM payment.³ We are reviewing both and will share what we confirm with clinics on the interest list. Nothing on this page is a promise of coverage or payment.

Regulatory status

On 09/03/2026, responding to a request under Section 513(g), FDA advised that evergait™ Go falls within 21 CFR 890.5360, Measuring Exercise Equipment (product code ISD), a Class II device type exempt from 510(k) premarket notification, subject to the limitations in 21 CFR 890.9.¹ A 513(g) response is FDA's view of how a device is classified. It is not FDA clearance or approval. evergait™ Go is not yet available for sale and today is used only in research studies under IRB approval.

Sources

U.S. Food and Drug Administration. Response to evergait, LLC under Section 513(g), reference C260017, dated 09/03/2026. FDA does not publish 513(g) responses; a copy is available on request.
Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule, remote therapeutic monitoring services, CY 2026. https://www.cms.gov/medicare/payment/fee-schedules/physician
Centers for Medicare & Medicaid Services. CY 2027 Physician Fee Schedule Proposed Rule (CMS-1848-P), 07/16/2026. https://www.cms.gov/medicare/payment/fee-schedules/physician

A home walking program your therapists can see

How it fits your clinic

Prescribe

Fit in a standard visit

Supervised sessions

Continue at home